NASDAQ:CING Cingulate (CING) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free CING Stock Alerts $1.10 +0.01 (+0.92%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$1.08▼$1.1250-Day Range$1.04▼$5.3452-Week Range$1.00▼$23.80Volume74,514 shsAverage Volume371,310 shsMarket Capitalization$1.03 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Cingulate alerts: Email Address Cingulate MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside627.3% Upside$8.00 Price TargetShort InterestHealthy0.29% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.77Based on 4 Articles This WeekInsider TradingAcquiring Shares$1,490 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($24.40) to ($9.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.88 out of 5 stars 3.2 Analyst's Opinion Consensus RatingCingulate has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Cingulate has a forecasted upside of 627.3% from its current price of $1.10.Amount of Analyst CoverageCingulate has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.29% of the float of Cingulate has been sold short.Short Interest Ratio / Days to CoverCingulate has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cingulate has recently decreased by 29.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCingulate does not currently pay a dividend.Dividend GrowthCingulate does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CING. Previous Next 2.7 News and Social Media Coverage News SentimentCingulate has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Cingulate this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for CING on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cingulate insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,490.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders38.43% of the stock of Cingulate is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.31% of the stock of Cingulate is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cingulate are expected to grow in the coming year, from ($24.40) to ($9.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cingulate is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cingulate is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCingulate has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Cingulate Stock (NASDAQ:CING)Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Read More CING Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CING Stock News HeadlinesMarch 28, 2024 | yahoo.com5 Easy Secrets of Super Agers That Can Help You Live a Long and Happy LifeMarch 20, 2024 | bizjournals.comCingulate can add $3.5M to latest stock offering as it navigates FDA drug approvalMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 19, 2024 | globenewswire.comCingulate to Participate in Benzinga All Live Access EventMarch 13, 2024 | msn.comADHD linked to unusual brain connectivity patterns in large-scale neuroimaging studyMarch 13, 2024 | msn.comBreakups Can Actually Change Your Brain Chemistry—Here's HowMarch 12, 2024 | nz.news.yahoo.comWhy you can't focus and what science says can helpMarch 12, 2024 | sg.news.yahoo.comHere's why you can't focus - and science-backed ways to help youMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 11, 2024 | msn.comSelf-hypnosis is soaring in popularity RN - I tried it after hearing that it could boost your mood and mental health from homeMarch 6, 2024 | globenewswire.comCingulate to Attend DCAT Week 2024 in New York CityFebruary 28, 2024 | bizjournals.comCingulate regains compliance with Nasdaq, maintaining key capital sourceFebruary 25, 2024 | msn.comUsing deep brain stimulation to map dysfunctional brain circuits linked to four disordersFebruary 22, 2024 | foxnews.comNew York woman reports improved mental health after undergoing brain electrode therapyFebruary 22, 2024 | msn.comBrain Pacemaker? New Stimulation Device Tested to Treat Depression Shows Promising ResultsFebruary 22, 2024 | msn.comResearchers use deep brain stimulation to map therapeutic targets for four brain disordersFebruary 22, 2024 | msn.comWoman Says Experimental Brain Implant Helped Her Lifelong Depression: 'Continuous Prozac'February 21, 2024 | dailymail.co.ukA pacemaker for the brain helped a woman with crippling depression. It may soon be available to moreFebruary 18, 2024 | msn.comAdditional study shows promise for low-intensity ultrasound as a non-invasive approach to alleviate painFebruary 14, 2024 | bizjournals.comCingulate adds three new members to board, following exits in DecemberFebruary 14, 2024 | msn.comMaltreatment linked to altered brain structure and spontaneous thought patterns in children, study findsFebruary 13, 2024 | finance.yahoo.comCingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of DirectorsFebruary 8, 2024 | bizjournals.comPharma company Cingulate raises $7.5M from public offeringFebruary 6, 2024 | markets.businessinsider.comCingulate Announces Closing of $7.5 Million Public OfferingFebruary 5, 2024 | msn.comBullied teens' brains show chemical change associated with psychosisFebruary 5, 2024 | msn.comBullying May Leave Teens at Greater Risk of PsychosisFebruary 5, 2024 | benzinga.comPeering Into Cingulate's Recent Short InterestSee More Headlines Receive CING Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cingulate and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/28/2024Next Earnings (Estimated)3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CING CUSIPN/A CIK1862150 Webwww.cingulate.com Phone913-942-2300FaxN/AEmployees15Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+627.3%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($32.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,235.83% Return on Assets-285.93% Debt Debt-to-Equity RatioN/A Current Ratio0.51 Quick Ratio0.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.87 per share Price / Book0.16Miscellaneous Outstanding Shares940,000Free Float577,000Market Cap$1.03 million OptionableNot Optionable Beta-0.92 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Shane J. Schaffer Pharm.D. (Age 48)PharmD, CEO, Principal Financial Officer & Chairman of the Board Comp: $491.96kDr. Laurie A. Myers M.B.A. (Age 66)Ph.D., Executive VP & COO Comp: $415.17kDr. Matthew N. Brams M.D. (Age 59)Executive VP & Chief Medical Officer Comp: $244.79kMs. Jennifer L. Callahan CPA (Age 53)CFO, Senior VP & Corporate Controller Dr. Raul R. Silva M.D. (Age 65)Executive VP & Chief Science Officer Thomas DaltonHead of Investor & Public RelationsMore ExecutivesKey CompetitorsBiodexa PharmaceuticalsNASDAQ:BDRXComera Life SciencesNASDAQ:CMRASciSparcNASDAQ:SPRCTenax TherapeuticsNASDAQ:TENXEvelo BiosciencesNASDAQ:EVLOView All CompetitorsInsidersJennifer L CallahanBought 55 shares on 3/15/2024Total: $1,490.50 ($27.10/share)Jennifer L CallahanBought 250 shares on 9/15/2023Total: $3,350.00 ($13.40/share)Peter J WerthBought 91,157 shares on 8/11/2023Total: $1.00 M ($11.00/share)Jennifer L CallahanBought 100 shares on 5/15/2023Total: $2,020.00 ($20.20/share)Jennifer L CallahanBought 200 shares on 5/12/2023Total: $4,320.00 ($21.60/share)View All Insider Transactions CING Stock Analysis - Frequently Asked Questions Should I buy or sell Cingulate stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cingulate in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CING shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CING, but not buy additional shares or sell existing shares. View CING analyst ratings or view top-rated stocks. What is Cingulate's stock price target for 2024? 3 brokerages have issued twelve-month price objectives for Cingulate's shares. Their CING share price targets range from $8.00 to $8.00. On average, they predict the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 627.3% from the stock's current price. View analysts price targets for CING or view top-rated stocks among Wall Street analysts. How have CING shares performed in 2024? Cingulate's stock was trading at $7.65 at the start of the year. Since then, CING stock has decreased by 85.6% and is now trading at $1.10. View the best growth stocks for 2024 here. Are investors shorting Cingulate? Cingulate saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 42,700 shares, a decline of 29.2% from the February 29th total of 60,300 shares. Based on an average trading volume of 1,680,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.3% of the shares of the stock are sold short. View Cingulate's Short Interest. When is Cingulate's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024. View our CING earnings forecast. When did Cingulate's stock split? Shares of Cingulate reverse split on the morning of Thursday, November 30th 2023. The 1-20 reverse split was announced on Thursday, November 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cingulate IPO? Cingulate (CING) raised $29 million in an initial public offering on Wednesday, December 8th 2021. The company issued 4,166,666 shares at a price of $6.00-$8.00 per share. How do I buy shares of Cingulate? Shares of CING stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CING) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.